Bexobrutideg
Pharmaceutical compound
From Wikipedia, the free encyclopedia
Bexobrutideg (NX-5948) is an investigational new drug that is being evaluated by Nurix Therapeutics for the treatment of relapsed and refractory B-cell malignancies, including chronic lymphocytic leukemia (CLL) and Waldenström macroglobulinemia. It is an orally bioavailable, brain-penetrant Bruton's tyrosine kinase degrader.[1]
| Identifiers | |
|---|---|
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C42H54N12O5 |
| Molar mass | 806.973 g·mol−1 |
| 3D model (JSmol) | |
| |
| |